SEARCH

SEARCH BY CITATION

References

  • 1
    Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003; 362:17331745.
  • 2
    Fouchier RA, Munster V, Wallensten A et al. Characterization of a novel influenza A virus HA subtype (H16) obtained from black-headed gulls. J Virol 2005; 79:28142822.
  • 3
    Lipatov AS, Govorkova EA, Webby RJ et al. Influenza: emergence and control. J Virol 2004; 78:89518959.
  • 4
    Tollis M, Di Trani L. Recent developments in avian influenza research: epidemiology and immunoprophylaxis. Vet J 2002; 164:202215.
  • 5
    Subbarao K, Klimov A, Katz J et al. Characterization of an avian influenza A (H5N1A/H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998; 279:393396.
  • 6
    Claas EC, De Jong JC, Van Beek R, Rimmelzwaan GF, Osterhaus AD. Human influenza virus A/HongKong/156/97 (H5N1A/H5N1) infection. Vaccine 1998; 10:977978.
  • 7
    Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1). Reported to WHO [http://www.who.int/csr/disease/avian_influenza/country/cases_table_2007_02_19/en/index.html].
  • 8
    Tweed SA, Skowronski DM, David ST et al. Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis 2004; 10:21962199.
  • 9
    Update on avian influenza in animals (type H5) [http://www.oie.int/downld/AVIAN%20INFLUENZA/a_AI-Asia.htm].
  • 10
    Zeitlin GA, Maslow MJ. Avian influenza. Curr Infect Dis Rep 2005; 7:193199.
  • 11
    Butler D. Vaccination will work better than culling, say bird flu experts. Nature 2005; 434:810.
  • 12
    Wood JM, Major D, Newman RW et al. Preparation of vaccines against H5N1 influenza. Vaccine 2002; 20(Suppl. 2):S84S87.
  • 13
    Kistner O, Barrett PN, Mundt W et al. A novel mammalian cell (Vero) derived influenza virus vaccine: development, characterization and industrial scale production. Wien Klin Wochenschr 1999; 111:207214.
  • 14
    Pau MG, Orphorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 2001; 19:27162721.
  • 15
    Beare AS, Hall TS. Recombinant influenza A viruses as live vaccines for man. Report to the Medical Research Council’s Committee on Influenza and other Respiratory Virus Vaccines. Lancet 1971; 2:12711273.
  • 16
    Florent G. Genotypic characterization and clinical evaluation of an influenza A/Texas/1/77 (H3N2)-like recombinant: RIT 4199. J Biol Stand 1979; 7:361368.
  • 17
    Florent G. Gene constellation of live influenza A vaccines. Arch Virol 1980; 64:171173.
  • 18
    Kilbourne ED, Schulman JL, Schild GC, Schloer G, Swanson J, Bucher D. Related studies of a recombinant reassortant influenza-virus vaccine. I. Derivation and characterization of virus and vaccine. J Infect Dis 1971; 124:449462.
  • 19
    Webby RJ, Perez DR, Coleman JS et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004; 363:10991103.
  • 20
    Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. Rescue of influenza A virus from recombinant reassortant DNA. J Virol 1999; 73:96799682.
  • 21
    Schickli JH, Flandorfer A, Nakaya T, Martinez-Sobrido L, Garcia-Sastre A, Palese P. Plasmid-only rescue of influenza A virus vaccine candidates. Philos Trans R Soc Lond B Biol Sci 2001; 356:19651973.
  • 22
    Marsh GA, Tannock GA. The role of reverse genetics in the development of vaccines against respiratory viruses. Expert Opin Biol Ther 2005; 5:369380.
  • 23
    Panigrahy B, Senne DA, Pearson JE. Presence of avian influenza virus (AIV) subtypes H5N2 and H7N1 in emus (Dromaius novaehollandiae) and rheas (Rhea americana): virus isolation and serologic findings. Avian Dis 1995; 39:6467.
  • 24
    Perdue ML, Wainright P, Palmieri S, Brugh M. In ovo competition between distinct virus populations in an avian influenza isolate. Avian Dis 1989; 33:695706.
  • 25
    Swayne DE, Beck JR, Perdue ML, Beard CW. Efficacy of vaccines in chickens against highly pathogenic Hong Kong H5N1 avian influenza. Avian Dis 2001; 45:355365.
  • 26
    Stone HD. Efficacy of avian influenza oil-emulsion vaccines in chickens of various ages. Avian Dis 1987; 31:483490.
  • 27
    Kandal AP, Skehel JJ, Pereira MS. Concepts and Procedures for Laboratory-based Influenza Surveillance. Atlanta, GA: Center for Disease Control, 1982.
  • 28
    Production of pilot lots of inactivated influenza vaccines from reassortants derived from avian influenza viruses. Interim biosafety assessment [http://www.who.int/csr/resources/publications/influenza/en/influenzaRMD2003_5.pdf].
  • 29
    Bradshaw GL, Schlesinger RW, Schartz CD. Effects of cell differentiation on replication of A/WS/33, WSN, PR8 influenza viruses in mouse brain cell cultures: biological and immunological characterization of products. J Virol 1989; 63:17041714.
  • 30
    Perkus ME, Tartaglia J, Paoletti E. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukoc Biol 1995; 58:113.
  • 31
    Wilson IA, Cox NJ. Structural basis of the immune recognition of influenza virus hemagglutinin. Annu Rev Immunol 1990; 8:737771.
  • 32
    Matrosovich M, Zhou N, Kawaoka Y, Webster R. The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. J Virol 1999; 73:11461155.
  • 33
    Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, Katz JM. Pathogenesis of avian influenza A (H5N1A/H5N1) viruses in ferrets. J Virol 2002; 76:44204429.
  • 34
    Maines TR, Lu XH, Erb SM et al. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol. 2005; 79: 1178811800.
  • 35
    Comai L, Tanese N, Tjian R. The TATA-binding protein and associated factors are integral components of the RNA polymerase I transcription factor, SL1. Cell 1992; 68:965976.
  • 36
    Pleschka S, Jaskunas R, Engelhardt OG, Zurcher T, Palese P, Garcia-Sastre A. A plasmid-based reverse genetics system for influenza A virus. J Virol 1996; 70:41884192.
  • 37
    Neumann G, Watanabe T, Ito H et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A 1999; 96:93459350.
  • 38
    Hoffmann E, Neumann G, Hobom G, Webster RG, Kawaoka Y. ‘Ambisense’ approach for the generation of influenza A virus: vRNA and mRNA synthesis from one template. Virology 2000; 267:310317.
  • 39
    Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 2000; 97:61086113.
  • 40
    Hoffmann E, Krauss S, Perez D, Webby R, Webster RG. Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 2002; 26:31653170.
  • 41
    Massin P, Rodrigues P, Marasescu M, Van Der Werf S, Naffakh N. Cloning of the chicken RNA polymerase I promoter and use for reverse genetics of influenza A viruses in avian cells. J Virol 2005; 79:1381113816.
  • 42
    U.S. Animal Health Association Report of the Committee on Transmissible Diseases of Poultry and other Avian Species. Criteria for determining that an avian influenza virus isolation causing an outbreak must be considered for eradication. In: Proceedings of the 98th Annual Meeting of the United States Animal Health Association. Grand Rapids, MI: U.S. Animal Health Association, 1994; 522.
  • 43
    WHO guidance on development of influenza vaccine reference viruses by reverse genetics [http://whqlibdoc.who.int/hq/2005/WHO_CDS_CSR_GIP_2005.6.pdf].
  • 44
    Ozaki H, Govorkova EA, Li C, Xiong X, Webster RG, Webby RJ. Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics. J Virol 2004; 78:18511857.
  • 45
    Nicolson C, Major D, Wood JM, Robertson JS. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005; 23:29432952.
  • 46
    Neumann G, Fujii K, Kino Y, Kawaoka Y. An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. Proc Natl Acad Sci U S A 2005; 102:1682516829.
  • 47
    Orlich M, Khatchikian D, Teigler A, Rott R. Structural variation occurring in the hemagglutinin of influenza virus A/turkey/Oregon/71 during adaptation to different cell types. Virology 1990; 176:531538.
  • 48
    Maher JA, DeStefano J. The ferret: an animal model to study influenza virus. Lab Anim (NY) 2004; 33:5053.
  • 49
    Robertson JS, Naeve CW, Webster RG, Bootman JS, Newman R, Schild GC. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 1985; 143:166174.
  • 50
    Oxford JS, Newman R, Corcoran T et al. Direct isolation in eggs of influenza A (H1N1) and B viruses with haemagglutinins of different antigenic and amino acid composition. J Gen Virol 1991; 1:185189.
  • 51
    Nguyen DC, Uyeki TM, Jadhao S et al. Isolation and characterization of avian influenza viruses, including highly pathogenic H5N1, from poultry in live bird markets in Hanoi, Vietnam, in 2001. J Virol 2005; 79:42014212.
  • 52
    Hoffmann E, Lipatov AS, Webby RJ, Govorkova EA, Webster RG. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci USA 2005; 102:1291512920.